This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Search

Menu

Close

Sign In or Register

Log Out Our MedicinesTherapy AreasExplore Content

Explore Content

Events

Downloadable Materials

Videos

Let's ConnectLet's ConnectContact usPfizer medical information

Adverse event reporting can be found at the bottom of the page

Menu

Close

MOA MOA MOA EfficacyEfficacyPALOMA-2 Study designPatient Characteristics Primary endpoint Secondary end point PALOMA-3Study design Patient Characteristics Primary endpoint Secondary end point SurvivalFinal analysis Subgroup analysis Prespecified groups Updated Subgroup analysis Safety Safety PALOMA pooled analysis Adverse reactions  & Laboratory abnormalities PALOMA 2 Adverse Events PALOMA 3 Adverse Events IBRANCE consistent  safety profile Pooled analysis of patients aged ≥65 years in the PALOMA trials No evidence of cumulative or delayed toxicity with up to 50 months Patients with visceral diseases GI ,  Liver toxicities, and QTC Dosing Dosing Once daily dosing Dose Modification Real-World EvidenceReal-world EvidenceIBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience Real-world data provide additional information Favorable progression free rates IRIS Study In the real world, IBRANCE benefits GuidelinesGuidelinesNCCN Guidelines ESMO Guidelines

Resources

Resources

Events

Materials

Videos

Information on how to access Ibrance® (palbociclib) prescribing information and adverse event reporting can be found at the bottom of the page.
Improved tumour response in first-line treatment with IBRANCE + letrozole versus placebo + letrozole (secondary end point)1
Adapted from Finn RS, et al. 2016.1
Data cut-off date: 26 February 2016.
*Defined as confirmed complete response or partial response.1
†Defined as confirmed CR, PR or SD for ≥24 weeks.1

CR= complete response; CBR= clinical benefit rate; ITT= intention-to-treat; LET= letrozole; ORR= objective response rate; PLA= placebo; PR= partial response; SD= stable disease.References:Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.Turner NC, et al. Ann Oncol. 2018;29(3):669-680.

Prescribing Information:

Bahrain Prescribing Information
Kuwait Prescribing Information
Oman Prescribing Information
Qatar Prescribing Information
UAE Prescribing Information

PP-IBR-QAT-0027

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

AccountSign Out

Copyright © 2024 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

 

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

 

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.
 

PP-UNP-BHR-0298

You are now leaving Pfizer

You are now leaving Pfizerpro and will be directed to our provider to complete your registration. Any personal information that you may find pre-populated from your Pfizerpro profile, or you may provide, will be governed by our Privacy Policy. Your data will not be used for any other purpose.

 

You are now leaving PfizerPro
​
You are leaving the Pfizer Portal - would you like to continue?
 

​​​​​​​